Aclarubicin

Description	Aclacinomycin A is a dual inhibitor of topoisomerase I and II. Aclacinomycin A is an anticancer drug which can reduce the tumor with minimal damage to normal cells. Aclacinomycin A shows potency against a wide variety of solid tumours and haematological malignancies. In A549, HepG2 and MCF-7 cells, Aclacinomycin A shows cytotoxic activity with IC50 values of 0.27μM, 0.32μM and 0.62μM, respectively. Aclacinomycin A induces cell apoptosis in these cells and the effects change to be necrosis when the incubation time is prolonged. Aclacinomycin A is demonstrated to increase the activity of both caspase-3 and caspase-8, thus inducing the activation of PARP. Apart from that, as an inhibitor of opoisomerases, Aclacinomycin A is found to induce DNA damage in V79 and irs-2 cells. Aclacinomycin A is used to treat acute leukaemias, lymphomas and other solid tumors through its inhibition of topo II.
Pathways	Cell Cycle/DNA Damage
Targets	Topoisomerase

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.